Related Experiment Videos
Immunotherapy for leukemia targeting the Wilms' tumor gene
1First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan. yasukawa@m.ehime-u.ac.jp
Leukemia & Lymphoma
|November 9, 2001
Summary
The Wilms' tumor (WT1) gene is a promising target for immunotherapy in leukemia. Researchers developed a T-cell therapy (TAK-1) that effectively targets and kills WT1-expressing leukemia cells while sparing normal cells.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- The Wilms' tumor (WT1) gene is highly expressed in leukemia cells, making it a potential target for cancer immunotherapy.
- WT1's preferential expression in malignant cells suggests its utility in developing targeted therapies.
Purpose of the Study:
- To investigate the potential of WT1 as a target for immunotherapy in leukemia.
- To establish and characterize a cytotoxic T lymphocyte (CTL) clone specific for WT1-derived peptides.
Main Methods:
- Established a CD8+ CTL clone (TAK-1) specific for a WT1-derived peptide presented by HLA-A24.
- Assessed TAK-1's cytotoxicity against various cell types, including leukemia, lymphoma, and normal cells.
- Investigated the effect of WT1 antisense oligonucleotides on TAK-1-mediated killing.
Main Results:
- TAK-1 demonstrated specific cytotoxicity against HLA-A24-positive leukemia cells expressing WT1.
- Cytotoxicity was dependent on WT1 expression and HLA-A24 presentation.
- TAK-1 did not harm normal bone marrow cells or WT1-negative lymphoma cells.
Conclusions:
- WT1-specific CTLs, like TAK-1, represent a viable immunotherapy strategy for leukemia.
- WT1 immunotherapy holds promise for treating both leukemia and other WT1-expressing solid tumors.